Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

$224.20 -1.28 (-0.57%)

(As of 11/26/2024 ET)

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for BDX.

Consensus Price Target

$283.00
26.23% Upside

According to the 7 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $283.00. The highest price target for BDX is $312.00, while the lowest price target for BDX is $270.00. The average price target represents a forecasted upside of 26.23% from the current price of $224.20.

Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

BDX Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$283.00	$282.63	$279.50	$283.86
Forecasted Upside	26.23% Upside	18.69% Upside	16.99% Upside	18.84% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Becton, Dickinson and Company Stock vs. The Competition

Type	Becton, Dickinson and Company	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	26.20% Upside	25,213.02% Upside	6.71% Upside
News Sentiment Rating	Positive News See Recent BDX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/1/2024	Evercore ISI 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$286.00 ➝ $290.00	+20.29%
10/1/2024	Citigroup 3 of 5 stars	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$255.00 ➝ $275.00	+14.08%
8/2/2024	Raymond James 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$275.00 ➝ $270.00	+12.55%
7/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$270.00 ➝ $280.00	+17.80%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$274.00	+21.82%
5/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$305.00 ➝ $312.00	+31.85%
❗[Investor Alert] Under-the-Radar Tech (Ad) While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO Click here for all the details about today's open round of investing.
12/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$310.00 ➝ $280.00	+17.52%
11/10/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$305.00 ➝ $280.00	+19.33%
1/3/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$250.00 ➝ $290.00	+14.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:25 PM ET.

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 22, 2024. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

Becton, Dickinson and Company recently reported earnings per share of $3.81, exceeding analyst expectations of $3.77, indicating strong financial performance and effective management.
The company has increased its quarterly dividend from $0.95 to $1.04, reflecting a commitment to returning value to shareholders and a healthy payout ratio of 70.03%.
Recent upgrades from multiple analysts, including Citigroup raising its rating to "buy" and increasing the price target to $275, suggest positive market sentiment and potential for stock appreciation.
The stock is currently trading around $236.30, which is near its 50-day moving average, indicating stability and potential for upward movement as it aligns with market trends.
Becton, Dickinson and Company has shown a revenue increase of 6.9% year-over-year, demonstrating growth in its core business and resilience in the medical instruments sector.

Becton, Dickinson and Company
Bear Case

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

Despite recent growth, the company's net margin of 8.55% may indicate challenges in maintaining profitability compared to industry peers.
Analysts have mixed opinions, with Raymond James recently lowering its price target from $275 to $270, which could signal concerns about future performance.
Institutional investors own 86.97% of the stock, which may lead to volatility if large shareholders decide to sell, impacting stock price stability.
The competitive landscape in the medical instruments sector is intense, with ongoing pressure from new entrants and technological advancements that could affect market share.
Current economic conditions and potential regulatory changes in the healthcare industry could pose risks to future revenue growth and operational efficiency.

BDX Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $283.00, with a high forecast of $312.00 and a low forecast of $270.00.
: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDX shares.
: According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 26.23% based on their 12-month stock forecasts.
: Over the previous 90 days, Becton, Dickinson and Company's stock had 1 upgrade by analysts.
: Becton, Dickinson and Company has been rated by research analysts at Citigroup, and Evercore ISI in the past 90 days.
: Analysts like Becton, Dickinson and Company more than other "medical" companies. The consensus rating for Becton, Dickinson and Company is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

This page (NYSE:BDX) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target